Shineco Inc. TYHT
Shineco Inc. (TYHT) is a US-listed (ADR) health care company, operating in Biotech and Pharma (Biotech). WealthyTec ranks it 2.16/10 for long-term growth consistency.
Shineco Inc. (TYHT) stock — key facts
Shineco Inc. (TYHT) is a US-listed (ADR) health care stock trading on NYSE / NASDAQ (ADR). The listing venue, sector standing and listing-status facts below are for orientation only — information, not investment advice.
- Listing venue
- US-listed (ADR)
- Exchange
- NYSE / NASDAQ (ADR)
- Sector
- Health Care · rank #20 of 31
- WealthyTec Rank
- 2.2Weak
- Dual / secondary listings
- None in our universe
- Listing status
- No delisting filing on record
- Market cap
- $86.5M
- P/E (TTM)
- —
- 2y EPS CAGR
- —
- Volume
- —
- 52w range
- —
Financial performance
Reported in —. TTM = trailing twelve months at last data refresh.
Companies similar to Shineco Inc.
Publicly traded companies similar to Shineco Inc. (TYHT) — Chinese health care stocks in the same sector and comparable size range. Peers include Sinovac Biotech Ltd., YiChang HEC ChangJiang Pharmaceutical Co Ltd, Shanghai Haohai Biological Technology Co Ltd, STAR Pharmaceutical Ltd, Shandong Xinhua Pharmaceutical Co Ltd and China Pharma Holdings Inc.. Each carries its WealthyTec Rank, market cap and, where a dated filing is on record, a listing-status flag — with a side-by-side comparison link where one exists. This is a factual grouping by sector and market cap for orientation only, not a recommendation to buy, sell or hold any security.
Embed this Rank card
Static SVG · dofollow attributionDrop TYHT’s WealthyTec Rank card into a blog post, README, or newsletter. It renders a server-generated snapshot and links back to this page. Free to use with attribution.
<a href="https://wealthytec.com/company/TYHT?ref=embed"><img src="https://wealthytec.com/api/badge/rank/TYHT.svg" alt="Shineco Inc. (TYHT) — WealthyTec Rank" width="380" height="104"></a>Information, not investment advice. The WealthyTec Rank and sector position are factual, observable orderings of long-term growth consistency — not a recommendation to buy, sell or hold, and not a valuation opinion.